Results 181 to 190 of about 23,127 (334)

Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5287-5293, June 2026.
ABSTRACT Aims Glucose‐dependent insulinotropic polypeptide (GIP) may exert both insulinotropic and glucagonotropic effects. While its insulinotropic action is reportedly attenuated or abolished with worsening of glycaemic control in type 2 diabetes (T2D), the relationship between GIP and glucagon secretion across different levels of glycaemic control ...
Zhenxi Wang, Weikun Huang, Rasmus S. Rasmussen, Michael Horowitz, Karen L. Jones, Christopher K. Rayner, Cong Xie, Tongzhi Wu   +7 more
wiley   +1 more source

Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries. [PDF]

JBRA Assist Reprod
Piazza MJ.
europepmc   +1 more source

Emerging role of insulin with incretin therapies for management of type 2 diabetes [PDF]

, 2011
Rupa Ahluwalia, Jiten Vora
core   +1 more source

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence

Obesity Reviews, Volume 27, Issue 6, June 2026.
ABSTRACT Next‐generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence‐based nutritional strategies to support safe and effective use of these agents remain limited.
Marie Spreckley, Cara F. Ruggiero, Adrian Brown   +2 more
wiley   +1 more source

GLP-1 is associated with perfectionism in Swedish women with anorexia nervosa, independent of BMI. [PDF]

Eat Weight Disord
Elm S, Petersson S, Carlsson M, Brudin L, Marteinsdottir I, Wanby P.   +5 more
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact. [PDF]

Med Sci (Basel)
Lee AA, Khotina VA, Kashirskikh DA, Voronko OE, Gasanov VAO, Vasiliev AV.   +5 more
europepmc   +1 more source

Not All Weight Loss Is Equal: Towards Muscle‐Preserving Therapies in Obesity

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
Joseph D. Abraham, Muhammad Shahzeb Khan, Stefan D. Anker   +2 more
wiley   +1 more source

Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
Central illustration: Pathophysiological mechanisms linking diabetes mellitus and cardiovascular disease. Chronic hyperglycaemia, insulin resistance, and low‐grade inflammation contribute to endothelial dysfunction, myocardial fibrosis, and cardiomyocyte apoptosis.
Lilian Anagnostopoulou, Nikolaos Ktenopoulos, Anastasios Apostolos, Christos Fragoulis, Panayotis Vlachakis, Paschalis Karakasis, Marios Sagris, Nikias Milaras, Maria Drakopoulou, Andreas Synetos, Ioannis Kyriazis, Ioannis Ioannidis, Costas Tsioufis, Konstantinos Toutouzas   +13 more
wiley   +1 more source

The Role of Incretins in Obstructive Sleep Apnea "GLP1RAs and GLP1RA/GIPRAs in OSA". [PDF]

J Diabetes
Fuentes AL, Dhami G, Pettus J, Akuthota P, Malhotra A.   +4 more
europepmc   +1 more source